- Adjuvant chemotherapy is associated with better survival in stage II/III mucinous colon adenocarcinoma.
Why this matters
- The prognosis and effect of adjuvant chemotherapy has not been clearly established in mucinous colon cancer, and this study is one of the largest to date.
- Retrospective analysis of records from the National Cancer Database (n=31,041) with stage II/III mucinous colon adenocarcinoma.
- Propensity-matched analysis: 3302 with stage II, 5564 with stage III.
- Funding: None disclosed.
- In adjusted analysis, there was no significant difference in survival between patients with stage II nonmucinous vs mucinous adenocarcinoma (HR, 0.99; P=.60).
- Survival in stage III disease favored nonmucinous disease (HR, 1.05; P<.001>
- Adjuvant chemotherapy was associated with better survival in mucinous adenocarcinoma:
- Stage II: 5 years: 78.4% vs 73.7%; 10 years: 61.9% vs 54.3% (HR, 0.79; P.
- Stage III: 5 years: 55.8% vs 36.8%; 10 years: 33.7% vs 19.2% (HR, 0.56; P
- Limited information on specific chemotherapy regimens, adverse events.